TB-500: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. TB-500: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. TB-500 is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

TB-500 is almost always mentioned in the same breath as BPC-157, and for good reason — they’re used together constantly. But TB-500 has its own, genuinely more complicated evidence story, built around a distinction that most discussions of this compound blur together entirely: the difference between TB-500 itself and the much larger protein it’s a small piece of.

Quick Facts

Class	Synthetic actin-binding peptide fragment
Parent compound	Thymosin Beta-4 (43-amino-acid protein)
Primary research use	Systemic tissue repair, cell mobilization
Administration	Subcutaneous or intramuscular
Typical effective range (community-reported)	2mg–2.5mg, once or twice weekly
Evidence tier	Preclinical only for the fragment itself; parent protein has separate human trial history in unrelated formulations
Regulatory status	Not approved anywhere; gray-zone research compound
WADA status	Prohibited at all times since 2011

The Story So Far

Here’s the distinction worth understanding before anything else in this guide: TB-500 is not thymosin beta-4. It’s a synthetic 7-amino-acid fragment — specifically the sequence Ac-LKKTETQ, corresponding to amino acids 17 through 23 — taken from the much larger, naturally occurring 43-amino-acid protein called thymosin beta-4 (Tβ4). That fragment happens to contain the region responsible for binding actin, the structural protein that gives cells their shape and lets them move, which is the basis for TB-500’s proposed mechanism. But it is a piece of the protein, not the protein itself, and that distinction turns out to matter enormously once you start looking at the human evidence.

Thymosin beta-4 itself has a real, substantial clinical development history — just not in the form or route that TB-500 is sold and used in. RegeneRx Biopharmaceuticals began developing full-length Tβ4 in the 2000s across several programs: topical formulations for skin wounds and pressure ulcers (RGN-137), an injectable formulation studied for safety in acute cardiac injury, and — the program that’s advanced the furthest — topical eye drops for dry eye disease and corneal conditions, developed as RGN-259 through a partnership that eventually became ReGenTree LLC and later HLB Therapeutics.

RGN-259’s clinical history is genuinely extensive. A Phase 2 trial in severe dry eye disease, published in 2015, found a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal staining at day 56 in a small trial. That led to Phase 3 trials (ARISE-1, ARISE-2, and ARISE-3) for dry eye disease — ARISE-3 missed its co-primary endpoints in 2022, hitting only a secondary comfort measure. The program pivoted toward a different indication, neurotrophic keratopathy, running parallel Phase 3 trials (SEER-2 in the US, SEER-3 in Europe). A 2023 published Phase 3 trial reported positive results — faster corneal healing and improved comfort compared to placebo. But SEER-3 then failed to meet its primary endpoint in 2024, which the sponsor attributed to an unusually strong placebo response. As of this writing, no New Drug Application or Biologics License Application has been filed for RGN-259 in either indication, and it remains unapproved anywhere.

None of that is about TB-500 the injectable fragment, though. It’s about a topical eye-drop formulation of the full-length protein, studied for eye conditions that have nothing to do with the tendon and systemic recovery research TB-500 is actually used for in this community. As of this writing, there are no completed, published Phase 2 or Phase 3 human trials of injectable TB-500 for musculoskeletal or systemic recovery indications at all.

On the regulatory side, TB-500 exists in the same general gray zone as BPC-157, though its specific FDA compounding classification history has been reported less consistently across sources than BPC-157’s — some accounts describe it avoiding the 2023 Category 2 restrictions because it was never widely used by compounding pharmacies in the first place, while others describe a 2026 reclassification into that same restricted category. What’s consistent across every source is that TB-500 is not FDA-approved for any use, has never been available through a legitimate prescription pathway the way BPC-157 briefly was, and its availability could be affected by the same Pharmacy Compounding Advisory Committee review scheduled for July 2026 that’s addressing BPC-157 and a number of other peptides.

What It Actually Does

TB-500 works through actin regulation. Actin is the structural protein that gives cells their shape and lets them move — think of it as part of the cell’s internal scaffolding and movement machinery. By binding actin, TB-500 is proposed to help cells migrate more effectively toward sites of injury, which is the mechanism behind its “systemic mobilization” reputation: rather than acting primarily at one local site, it’s theorized to help recruit repair-oriented cells from elsewhere in the body toward the area that needs them. It’s also proposed to support new blood vessel formation and reduce inflammation at injury sites, mechanisms shared with several other compounds in our regenerative category.

What the Research Shows

This is the section where the fragment-versus-parent-protein distinction matters most, so it’s worth restating plainly: the evidence base splits cleanly into two categories that are frequently — and incorrectly — treated as one.

Full-length thymosin beta-4, in topical and ophthalmic formulations, has a real and reasonably extensive human clinical trial history. The RGN-259 dry eye and neurotrophic keratopathy program ran through multiple Phase 2 and Phase 3 trials over roughly two decades, with genuinely mixed results — some positive signals, some missed primary endpoints, no approval yet. A separate injectable formulation of the full-length protein was studied for safety in acute cardiac injury under an active investigational new drug program, which is meaningful institutional confidence in the parent molecule’s safety profile specifically.

TB-500, the injectable fragment actually sold and used for systemic tissue recovery, has essentially none of that. The preclinical animal literature — covering cardiac, musculoskeletal, neurological, and ophthalmic models — is real and reasonably consistent. But there are no completed, published human trials of this specific fragment, in this specific injectable form, for the tendon, ligament, or systemic recovery applications the research community actually uses it for.

This isn’t a subtle distinction, and it’s one that a lot of the commercially-written material on this compound blurs together, sometimes citing RGN-259’s eye-drop trial results as though they support injectable TB-500 for tendon recovery. They don’t — different molecule size, different formulation, different route, different condition entirely.

How It Compares

TB-500 sits alongside BPC-157, GHK-Cu, and KPV in the regenerative category. For the full four-way comparison across mechanism, evidence, and use case, see our BPC-157 guide. The version most relevant to TB-500 specifically:

	TB-500	BPC-157
Mechanism	Actin regulation, systemic cell mobilization	Angiogenesis, fibroblast activation, local + systemic repair
Scope of action	Systemic — mobilizes repair resources from elsewhere in the body	Both local (injection site) and systemic, depending on route
Human trial data	None for the injectable fragment itself; parent protein has separate topical/ophthalmic trial history	One unpublished Phase 2 RCT; otherwise minimal
Typical combination use	Almost always paired with BPC-157 (The Wolverine Blend)	Almost always paired with TB-500

The practical distinction that makes the pairing make sense: BPC-157 tends to activate repair processes at the site of injury, while TB-500 is theorized to mobilize the body’s broader repair resources toward that site. Whether or not that theoretical division holds up under future human research, it’s the consistent rationale behind why these two compounds are so rarely discussed separately.

Who Shouldn’t Use This

TB-500 has no approved label anywhere, so there’s no official contraindications list. Based on the preclinical literature and the concerns most consistently raised in research discussion:

• Personal history of cancer or active malignancy. The same theoretical pro-angiogenic caution that applies to BPC-157 applies here — some literature has specifically associated thymosin beta-4 with increased metastatic potential in certain tumor models, which makes this a concern worth taking seriously rather than dismissing as boilerplate caution.
• Competitive athletes subject to drug testing. TB-500 and thymosin beta-4 derivatives have been on the WADA Prohibited List since 2011, banned at all times, with reported detection windows of roughly 30–45 days. It’s also banned in horse racing, for context on how seriously this particular substance is treated in tested sport.
• Pregnancy or breastfeeding. No human safety data exists in this context.

Beyond that, no established absolute contraindications exist in the published literature — reflecting thin data rather than a confirmed absence of risk.

Common Myths, Addressed

“TB-500 has been studied in human eye and heart trials.” Not accurately. Those trials studied full-length thymosin beta-4 in topical eye-drop and cardiac-safety formulations — a different molecule, in a different form, for different conditions. TB-500 the injectable fragment has no completed human trials of its own.

“Since it’s the same protein family as a drug with real trials, it’s basically pre-validated.” A shared mechanism of interest doesn’t transfer clinical evidence between a full 43-amino-acid protein and a synthetic 7-amino-acid fragment of it, especially across completely different administration routes. This is a real and common point of confusion worth actively correcting, not a technicality.

What Researchers Are Actually Experiencing

Given how little human trial data exists specifically for injectable TB-500, community-reported experience is doing even more of the informational work here than it does for BPC-157.

The dominant theme in community discussion is the pairing with BPC-157 — the two are used together so consistently that discussing TB-500 in isolation is almost unusual in practice. Reports of tolerability are generally favorable, with mild fatigue or lethargy in the first day or two after higher doses being the most commonly mentioned effect, particularly during loading phases.

Because there’s no dominant clinical dosing frequency to anchor community practice the way there is for compounds with real trial data, TB-500 protocols are noticeably more varied across community discussion than most other compounds in this guide series — daily, weekly, and twice-weekly approaches are all commonly discussed, without a clear consensus on which is superior.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and — more than almost any other compound in this guide series — there is no human trial data to check it against at all.

The Practical Basics

Research Ranges

Protocol	Research Range	Frequency
Daily	500mcg	Once daily, subcutaneous
Weekly	2mg	Once weekly, subcutaneous
Loading / acute injury	2mg	Twice weekly for 4–6 weeks, then reduce to weekly

Unlike most compounds in this guide series, there isn’t one dominant frequency — daily, weekly, and twice-weekly protocols are all commonly discussed. The frequency chosen shapes the per-injection dose: at 500mcg daily, the weekly total is roughly 3.5mg; at 2mg once or twice weekly, the weekly total lands in a similar range, just concentrated into fewer injections.

Worked Dose Math

At 5mg/mL (a 10mg vial reconstituted with 2mL BAC water):

• 500mcg (0.5mg) → 0.1mL → 10 units
• 2mg → 0.4mL → 40 units

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe.

Vial Planning

A 10mg vial at 5mg/mL gives you 10mg total. On a 2mg-once-weekly protocol, that’s 5 weeks per vial. On a daily 500mcg protocol, closer to 20 days. Because TB-500 protocols vary more than most compounds in this guide series, it’s worth deciding on your specific frequency before ordering rather than assuming a standard.

Reconstitution and Storage — The Short Version

TB-500 reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days — the same standard approach used across nearly every compound in this series. For the complete process and troubleshooting, see our dedicated reconstitution and storage guide.

Sourcing

Given the complete absence of any regulated supply chain — TB-500 has never had the brief compounding-pharmacy availability BPC-157 did — sourcing scrutiny matters as much here as for any compound in this guide series. See our full guide on reading a Certificate of Analysis and vetting a vendor.

Administration

Subcutaneous injection is standard for systemic recovery applications. Intramuscular injection near a specific injury site is used by some researchers for more targeted effects, following the same rationale as BPC-157’s local administration. No fasting requirement.

Best Practices

• Decide on a frequency before you start, given how much more variation exists in community practice here than for most compounds — don’t assume a default exists.
• Track fatigue specifically, since mild lethargy in the first day or two after higher doses is one of the more commonly reported effects.
• Rotate injection sites as standard practice.
• Track your protocol from day one — dose, frequency, injection date, and observed effects, at minimum.

Common Mistakes to Avoid

• Assuming the eye-drop and cardiac trial data for thymosin beta-4 applies to injectable TB-500 — it doesn’t, given the different molecule size, formulation, and route involved.
• Not recording the reconstitution volume, turning every dose calculation into a guess.
• Overlooking the WADA prohibition if you’re a competitive athlete, independent of domestic FDA status.
• Picking a frequency arbitrarily without understanding that community practice here is genuinely split rather than converged on one standard.

What Happens If You Stop

As with BPC-157, there’s no published research addressing discontinuation effects, and this isn’t a compound typically used as an indefinite ongoing intervention the way the GLP-1 or GH-axis compounds are. Community use overwhelmingly frames it as tied to a specific recovery objective — an injury, a defined protocol window — with tapering or discontinuation once that objective is met, rather than a compound expected to produce a rebound effect if stopped.

What to Expect, Week by Week

• Days 1–7: No dramatic acute effect typically reported; mild fatigue after higher doses is the most commonly noted early experience.
• Weeks 2–4: For injury-focused protocols, this is when community reports of noticeable recovery improvement most commonly begin to appear — though, as with BPC-157, this varies enormously by injury type.
• Weeks 4–6+ (if loading): Many loading protocols transition to a reduced maintenance frequency in this window.

Individual timelines vary substantially, and this pattern comes almost entirely from community report — there is no trial data to benchmark it against.

Combining With Other Compounds

TB-500 is combined with BPC-157 more consistently than almost any other pairing in this entire guide series — sold pre-blended as The Wolverine Blend for exactly this reason. The rationale is genuinely complementary rather than redundant: BPC-157’s local and systemic repair activation alongside TB-500’s proposed systemic cell mobilization, addressing recovery from two different mechanistic angles at once.

Common Questions

Is TB-500 the same thing as thymosin beta-4? No — TB-500 is a synthetic 7-amino-acid fragment of the much larger, naturally occurring 43-amino-acid thymosin beta-4 protein. They’re related but not interchangeable, and human trial data for one doesn’t transfer to the other.

If thymosin beta-4 has real clinical trials, why doesn’t that count for TB-500? Because those trials studied a different molecule (the full-length protein, not the fragment), in different formulations (topical eye drops, an IV cardiac safety study), for different conditions (dry eye, corneal healing, cardiac injury) entirely unrelated to the tendon and systemic recovery use TB-500 is actually used for.

Is TB-500 legal to buy? It’s sold as a research-use-only compound and is unscheduled in that specific sense. It has never been available through a legitimate compounding-pharmacy or prescription pathway the way BPC-157 briefly was.

Can I use this if I compete in tested sport? No safely — it’s been on the WADA Prohibited List since 2011, banned at all times.

Before You Start

A quick checklist to run through before your first dose:

• Understand that TB-500 itself has no completed human trials, and are comfortable with that tradeoff
• Considered whether you have a personal history of cancer, and sought medical guidance if so
• Confirmed you’re not subject to competitive drug testing, or accepted that risk knowingly
• Decided on a dosing frequency, given how much community practice varies here
• Have a tracking method ready for dose, frequency, and observed effects
• Sourced with real scrutiny, given the complete absence of a regulated supply chain

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose	Frequency
Daily	500mcg	Once daily
Standard weekly	2mg	Once weekly
Loading / acute injury	2mg	Twice weekly for 4–6 weeks, then reduce

Where to Go From Here

• The Regenerative Compound Group — BPC-157, TB-500, GHK-Cu, and KPV compared in full
• The Wolverine Blend — BPC-157 and TB-500 pre-combined
• BPC-157: The Complete Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.